{"id":"W4309048303","doi":"10.1097/ppo.0000000000000635","title":"Antibody-Drug Conjugates in Myeloid Leukemias","year":2022,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Antibody-drug conjugate; Medicine; Calicheamicin; Monoclonal antibody; Cancer research; Targeted therapy; Leukemia; Cytotoxic T cell; Drug; Antibody; Immunology; Cancer; Oncology; Pharmacology; CD33; Internal medicine; Stem cell; Biology; In vitro","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002304329,0.0004389739,0.001884176,0.0003966883,0.0003032487,0.000104868,0.001057284,0.0001654316,0.007770211],"category_scores_gemma":[0.0002752746,0.0002519322,0.0006572069,0.0008313602,0.0002266662,0.00008004112,0.0004155961,0.004064037,0.0001252752],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.05972414,"about_ca_system_score_gemma":0.05513755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009156674,"about_ca_topic_score_gemma":0.00007436473,"domain_scores_codex":[0.9961267,0.0006180083,0.0009822258,0.0004148576,0.00107714,0.0007810414],"domain_scores_gemma":[0.9977227,0.0006783507,0.0004920274,0.0007461566,0.00007803125,0.0002827187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001013934,0.00005424625,0.00001586611,0.009062627,0.0004877047,0.002255639,0.0004975074,0.00002778022,0.000003303112,0.00003736559,0.01346614,0.9739904],"study_design_scores_gemma":[0.004113668,0.00005968997,0.000004261139,0.01228808,0.0006681581,0.0108267,0.0001565902,0.00009288453,0.000002936308,0.00009099129,0.9714493,0.0002467053],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001702724,0.9946062,0.000003352524,0.0004255894,0.0007965534,0.000877049,0.00003062233,0.00002525067,0.003065128],"genre_scores_gemma":[0.00003435513,0.9939141,0.00001682386,0.0003499072,0.001796347,0.0001798582,0.00007453135,0.0001170029,0.003517066],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9737437,"threshold_uncertainty_score":0.9999933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1013060180836298,"score_gpt":0.4469558710984948,"score_spread":0.345649853014865,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}